Becton, Dickinson and Company $BDX Shares Purchased by National Pension Service

National Pension Service grew its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 7.0% during the second quarter, Holdings Channel reports. The firm owned 596,647 shares of the medical instruments supplier’s stock after acquiring an additional 38,982 shares during the quarter. National Pension Service’s holdings in Becton, Dickinson and Company were worth $90,291,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of BDX. Imprint Wealth LLC acquired a new position in shares of Becton, Dickinson and Company in the third quarter valued at approximately $25,000. SHP Wealth Management purchased a new position in Becton, Dickinson and Company in the 4th quarter valued at approximately $26,000. Meeder Asset Management Inc. increased its position in shares of Becton, Dickinson and Company by 152.2% during the first quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier’s stock worth $27,000 after acquiring an additional 102 shares during the period. Main Street Group LTD acquired a new stake in shares of Becton, Dickinson and Company in the first quarter valued at $29,000. Finally, Bell Investment Advisors Inc purchased a new position in Becton, Dickinson and Company in the second quarter valued at $29,000. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Analyst Ratings Changes

BDX has been the topic of several recent research reports. Citigroup restated a “buy” rating on shares of Becton, Dickinson and Company in a report on Thursday, August 13th. Jefferies Financial Group restated a “buy” rating and issued a $210.00 price objective on shares of Becton, Dickinson and Company in a report on Thursday, August 6th. Piper Sandler increased their target price on Becton, Dickinson and Company from $161.00 to $175.00 and gave the company a “neutral” rating in a report on Friday, August 7th. Wells Fargo & Company raised their price target on Becton, Dickinson and Company from $161.00 to $170.00 and gave the company an “equal weight” rating in a research note on Friday, August 7th. Finally, Royal Bank Of Canada increased their price objective on Becton, Dickinson and Company from $180.00 to $190.00 and gave the company a “sector perform” rating in a report on Thursday, August 13th. Eight investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $187.67.

Insider Buying and Selling at Becton, Dickinson and Company

In other news, EVP Michael Feld sold 165 shares of Becton, Dickinson and Company stock in a transaction on Wednesday, August 26th. The shares were sold at an average price of $188.49, for a total value of $31,100.85. Following the transaction, the executive vice president directly owned 19,720 shares of the company’s stock, valued at $3,717,022.80. The trade was a 0.83% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of the company’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $180.84, for a total transaction of $440,887.92. Following the completion of the sale, the executive vice president owned 14,856 shares of the company’s stock, valued at approximately $2,686,559.04. This trade represents a 14.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 8,005 shares of company stock valued at $1,423,580. 0.40% of the stock is currently owned by insiders.

Becton, Dickinson and Company Stock Performance

Shares of BDX stock opened at $177.85 on Friday. The stock’s 50-day moving average is $172.51 and its two-hundred day moving average is $160.65. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.51 and a current ratio of 0.87. Becton, Dickinson and Company has a 1 year low of $127.59 and a 1 year high of $193.07. The firm has a market cap of $49.00 billion, a price-to-earnings ratio of 53.57, a PEG ratio of 12.43 and a beta of 0.21.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.14 by $0.09. The firm had revenue of $4.98 billion during the quarter, compared to analysts’ expectations of $4.89 billion. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%.The business’s revenue was up 5.4% on a year-over-year basis. During the same period in the prior year, the firm earned $3.68 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Analysts predict that Becton, Dickinson and Company will post 12.67 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th will be given a dividend of $1.05 per share. The ex-dividend date is Wednesday, September 9th. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.4%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 126.51%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells products used by healthcare providers, researchers and pharmaceutical companies. Founded in 1897 by Maxwell Becton and Fairleigh Dickinson, the company is headquartered in Franklin Lakes, New Jersey.

BD’s products support medication delivery, infection prevention, diagnostics and surgical care. Its portfolio includes needles, syringes, injection devices, infusion products, medication-management systems, specimen-collection products, laboratory instruments and diagnostic technologies.